Hepatitis C elimination: a Public Health Perspective

Dhiman, Radha K.; Grover, Gagandeep Singh; Premkumar, Madhumita

doi:10.1007/s11938-019-00240-7

Cited by 21 publications

(25 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…infections [4,5]. However, the outcome of antiviral therapies could be limited by several factors, including the possible emergence of drug-resistant viral variants.…”

Section: And 11mentioning

confidence: 99%

“…An effective vaccine against these viruses remains to be developed. Within the past decade, advancement in the development of anti-viral regimens has improved the situation, particularly in controlling HCV infections [4,5]. However, the outcome of antiviral therapies could be limited by several factors, including the possible emergence of drug-resistant viral variants.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry

Shahid

Qadir

Yang

et al. 2020

Viruses

View full text Add to dashboard Cite

Microvirin (MVN) is one of the human immunodeficiency virus (HIV-1) entry inhibitor lectins, which consists of two structural domains sharing 35% sequence identity and contrary to many other antiviral lectins, it exists as a monomer. In this study, we engineered an MVN variant, LUMS1, consisting of two domains with 100% sequence identity, thereby reducing the chemical heterogeneity, which is a major factor in eliciting immunogenicity. We determined carbohydrate binding of LUMS1 through NMR chemical shift perturbation and tested its anti-HIV activity in single-round infectivity assay and its anti-hepatitis C virus (HCV) activity in three different assays including HCVcc, HCVpp, and replicon assays. We further investigated the effect of LUMS1 on the activation of T helper (Th) and B cells through flow cytometry. LUMS1 showed binding to α(1-2)mannobiose, the minimum glycan epitope of MVN, potently inhibited HIV-1 and HCV with EC50 of 37.2 and 45.3 nM, respectively, and showed negligible cytotoxicity with CC50 > 10 µM against PBMCs, Huh-7.5 and HepG2 cells, and 4.9 µM against TZM-bl cells. LUMS1 did not activate Th cells, and its stimulatory effect on B cells was markedly less as compared to MVN. Together, with these effects, LUMS1 represents a potential candidate for the development of antiviral therapies.

show abstract

“…infections [4,5]. However, the outcome of antiviral therapies could be limited by several factors, including the possible emergence of drug-resistant viral variants.…”

Section: And 11mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry

Shahid

Qadir

Yang

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Mobilization of state-sponsored HCV elimination programs in a global coalition against HCV has occurred in Egypt, India, Mongolia, China, Australia, and Brazil. 95 Through a unique collaboration between Gilead Sciences and the nation of Georgia, the world's first HCV elimination program was launched in 2015 with an ambitious goal of a 90% reduction in HCV prevalence by 2020. 95 Since its initiation, over onethird of persons living with HCV in Georgia have been identified and linked to care and treatment.…”

Section: Large Scale Effortsmentioning

confidence: 99%

Treatment of Hepatitis C: A New Paradigm toward Viral Eradication

Squires

Balistreri

2020

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…The recent discovery of well‐tolerated and highly efficacious pan‐genotypic (active against all HCV genotypes) direct acting antivirals (DAAs) has revolutionized the treatment landscape for HCV infection, with SVR (or cure) rates of almost 100% for most patient populations, making global HCV elimination a distinct possibility (Dhiman et al, 2019). Due to the success of these HCV regimens in curing the infection, the biomarker strategy for HCV therapy is relatively simple and well defined.…”

Section: Hcv Infectionmentioning

confidence: 99%

Biomarkers for the clinical development of antiviral therapies

Dorr

Krishnan

et al. 2020

Cytometry Part B Clinical

View full text Add to dashboard Cite

With the morbidity and mortality associated with the COVID‐19 pandemic that we are witnessing this year, the risks posed by emerging viral diseases to global health are all too obvious. This pandemic highlights the importance of antiviral drug discovery, which targets emerging viral pathogens, as well as existing pathogenic viruses that undergo continuous evolution. Drug discovery and development is a long and resource intensive process; however, the use of biomarkers can accelerate clinical development of antivirals by providing information regarding diagnosis of specific viral infections, status of infection, potential safety parameters, and antiviral responses. In clinical practice, many of the biomarkers initially utilized to support clinical development are also used for patient care. While viral load is a standard and essential biomarker used to detect the desired viral suppression induced by an antiviral agent, it has become apparent that additional biomarkers, whether related to the virus, the host or as a consequence of the drug's mechanistic effects, are also important for monitoring clinical outcomes associated with an antiviral therapy. This review summarizes the biomarkers used in the clinical development (as well as in clinical practice, where appropriate) of antiviral therapies for hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and severe acute respiratory syndrome coronavirus 2.

show abstract

Hepatitis C elimination: a Public Health Perspective

Cited by 21 publications

References 48 publications

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry

An Engineered Microvirin Variant with Identical Structural Domains Potently Inhibits Human Immunodeficiency Virus and Hepatitis C Virus Cellular Entry

Treatment of Hepatitis C: A New Paradigm toward Viral Eradication

Biomarkers for the clinical development of antiviral therapies

Contact Info

Product

Resources

About